June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Non-inferiority of subretinal versus intravitreal injection regarding photoreceptor layer thickness
Author Affiliations & Notes
  • Guy Alex Ochakovski
    University Eye Hospital, Centre for Ophthalmology, University Hospital Tuebingen, Tübingen, Germany
  • Tobias Peters
    STZ eyetrial at the Centre for Ophthalmology, University Hospital Tuebingen, Tübingen, Germany
  • Stylianos Michalakis
    Center for Integrated Protein Science Munich CiPSM at the Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany
  • Barbara Wilhelm
    STZ eyetrial at the Centre for Ophthalmology, University Hospital Tuebingen, Tübingen, Germany
  • K. Ulrich Bartz-Schmidt
    University Eye Hospital, Centre for Ophthalmology, University Hospital Tuebingen, Tübingen, Germany
  • M Dominik Fischer
    University Eye Hospital, Centre for Ophthalmology, University Hospital Tuebingen, Tübingen, Germany
    STZ eyetrial at the Centre for Ophthalmology, University Hospital Tuebingen, Tübingen, Germany
  • Footnotes
    Commercial Relationships   Guy Alex Ochakovski, None; Tobias Peters, None; Stylianos Michalakis, Eyeserv GmbH (P); Barbara Wilhelm, None; K. Ulrich Bartz-Schmidt, None; M Dominik Fischer, NightStaRx Ltd. (C), NightStaRx Ltd. (F), Oxford University Innovation (P)
  • Footnotes
    Support  Tistou & Charlotte Kerstan Foundation
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4100. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Guy Alex Ochakovski, Tobias Peters, Stylianos Michalakis, Barbara Wilhelm, K. Ulrich Bartz-Schmidt, M Dominik Fischer; Non-inferiority of subretinal versus intravitreal injection regarding photoreceptor layer thickness. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4100.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Despite ever growing adoption of subretinal (SR) and intravitreal (IVT) injection methods for vector delivery in ocular gene therapy trials, concerns regarding the SR approach in terms of possible deleterious effects on the outer retina are yet to be cleared. We tested the SR injection for quantifiable and qualitative structural changes in the outer retina and compared them for non-inferiority to the IVT approach in non-human primates.

Methods : In a fully GLP compliant toxicology study, 22 cynomolgus monkeys (ages 4-5, 11 male) underwent single intraocular injections with rAAV2/8 or vehicle. 18 animals received SR injections with vehicle (n = 6) or vector (n = 12), 4 animals received vector as IVT injection. Optical coherence tomography was used to visualise retinal layers before and at two timepoints after the injection (2 and 13 weeks). Outer nuclear layer (ONL) thickness was used as outcome measure to quantify change from baseline for a non-inferiority analysis. Clinical significance threshold for inferiority (M1 value) was set to an ONL reduction equivalent of three line vision loss based on previous studies (Matsumoto et al., Am J Ophthalmol. 148(1):105, 2009). Preservation of the physiological elongation of photoreceptor outer segments in the fovea (foveal bulge) was used as a secondary, qualitative measure of visual outcome.

Results : In the SR group the average ONL change from baseline after 2 weeks was -6.54 ± 5.16µm (mean±s.d). In the IVT group the average change at 2 weeks was +1.50 ± 4.36µm. At 13 weeks, the SR group maintained a difference of -6.54 ± 9.66µm from baseline while IVT group gained +1.00 ± 4.24µm in ONL thickness on average. The foveal bulge was preserved in 9 out of 13 eyes (69%) in the SR group and in all eyes in the IVT group.

Conclusions : The SR injection has proven not to be inferior in a clinically significant manner to the IVT injection in terms of ONL thickness loss and estimated VA losses. Although SR injection was shown to be followed by some limited degree of ONL thinning, the observed effect including the 95% confidence intervals were under the predefined clinical significance threshold both after 2 and 13 weeks.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×